Illumina Inc. reported first‑quarter 2026 revenue of $1.09 billion, a 4.8% increase from the $1.041 billion earned in the same period a year earlier. Non‑GAAP operating margin expanded to 21.9%, up 150 basis points from 20.4% in Q1 2025, while non‑GAAP earnings per share reached $1.15, beating analyst expectations of $1.06–$1.075 by $0.07–$0.09. The earnings beat was driven by a 9% rise in instrument revenue, largely from the NovaSeq X platform, and a 20% ex‑China growth in clinical consumables that offset a 12% decline in research consumables.
The company’s consumables segment generated $726 million in revenue, up 4% YoY. Clinical sequencing consumables, which account for more than 65% of consumables revenue, grew 20% ex‑China, reflecting strong demand from clinical laboratories. In contrast, research and applied consumables fell 12% ex‑China, a headwind attributed to funding uncertainty in the research market. Sequencing instruments contributed $118 million, up 9% YoY, driven by robust NovaSeq X placements, while sequencing services and other revenue rose 7% to $151 million. The microarrays business declined 20% on a rest‑of‑world organic basis, largely due to the loss of a large direct‑to‑consumer customer.
Management raised its full‑year 2026 revenue guidance to a range of $4.52 billion to $4.62 billion, a $20 million increase at the midpoint from the prior guidance. The company also lifted its non‑GAAP diluted EPS outlook to $5.15–$5.30, reflecting confidence in continued clinical market strength and progress on its multi‑omics initiatives. The guidance increase signals management’s belief that the strong demand for NovaSeq X and the expanding clinical consumables market will sustain higher revenue growth than previously expected.
CEO Jacob Thaysen noted that “Illumina delivered a strong start to 2026, reflecting strength of the Illumina ecosystem and progress against our strategy.” CFO Ankur Dhingra highlighted that the company’s revenue of $1.09 billion was $20 million above the midpoint of its guidance, driven by better‑than‑expected instrument sales and clinical consumable sales. The company also emphasized the need to scale NovaSeq X supply amid ongoing constraints and the unresolved “China problem,” which continues to limit growth in that market.
Illumina’s cash position remains robust at $1.16 billion, supporting ongoing investment in its multi‑omics strategy while generating $251 million in free cash flow during the quarter. The company also announced an additional $1.5 billion in share repurchases, underscoring confidence in its financial position and commitment to returning value to shareholders.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.